



Providers: Consider Monoclonal Antibodies (mAbs) for Treatment of Patients With Early COVID-19, or for Postexposure Prophylaxis

Let's save lives.

Get the Facts

How does it work?

Monoclonal antibodies directly neutralize the SARS-CoV-2 virus to help prevent progression of the disease.

How can I get mAb therapy for my patients?

Depending on which monoclonal antibody (mAb) is used, the therapy is administered by IV infusion or four subcutaneous injections. Patients can receive it at an outpatient infusion center, the emergency department of some hospitals, nursing homes, or in their homes. Monoclonal antibody therapy requires a prescription from a doctor or medical provider. The medication is free, but patients may be responsible for a co-pay.

Are there any side effects?

Side effects are usually mild and may include nausea, diarrhea, or skin rashes. Although uncommon, severe allergic reactions may occur.

Consider mAbs for:

Treatment of patients with mild to moderate COVID-19 who meet all the following criteria:

- 12+** Are 12 or older and weigh at least 88 pounds (40 kg),
-  Have a positive viral test (PCR or antigen) for SARS-CoV-2,
-  Are at high risk for progression of COVID-19 to severe illness, *and*
-  Are not hospitalized due to COVID-19 and do not require supplemental oxygen

Patients who fit these criteria must receive mAb therapy within 10 days of symptom onset.

Postexposure prophylaxis for people who meet all the following criteria:

- 12+** Are 12 or older and weigh at least 88 pounds (40 kg),
-  Are not fully vaccinated, OR not anticipated to mount an adequate immune response to complete vaccination,
-  Are at high risk for progression of COVID-19 to severe illness, *and*
-  Are exposed to a person with COVID-19, OR are at high risk of being exposed to someone with COVID-19.

Talk to your patients about mAb today.

More questions? Visit vdh.virginia.gov/mabs/